Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 26, 2020
Daily News
October 26, 2020
- CureApp Launches Prescription Platform for Therapeutic Apps
October 26, 2020
- Mitsubishi Chemical Taps Belgium-Born Gilson as Its First Foreign CEO
October 26, 2020
- 1st Working Group Meeting for Prioritization of “Stable Supply Medicines” Set for Early November
October 26, 2020
- MHLW Continues to Collect Info on WHO-Led Study on Veklury
October 26, 2020
- Exploratory Trial of Neuro-Protective/Regenerative Sheets to Be Launched for CTS: Osaka Univ., NIMS, Nippon Zoki
October 26, 2020
- Nichi-Iko’s Remicade Biosimilar Adds Ankylosing Spondylitis Use
October 26, 2020
- Sanwa Kagaku’s SHPT Drug Meets Primary Goal in Japan PIII
October 26, 2020
- Cyberattacks Leak Data from Shionogi’s Taiwan Subsidiary
October 26, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…